BenevolentAI's Strategic Shareholder Letter for 2023

BenevolentAI, a company specializing in AI-driven drug discovery, has released a shareholder letter for 2023, detailing its strategic plan for 2024. The company has seen significant progress in enhancing its AI-augmented drug discovery platform, forming strategic partnerships with Merck KGaA and AstraZeneca, and progressing in its lead asset for the treatment of ulcerative colitis. BenevolentAI aims to strengthen its commercial capabilities and operational effectiveness for the upcoming year.